Abstract
About this talk
Biologic drugs and nucleic acid therapeutics, such as proteins, antibodies, vaccines, mRNA, and siRNA, represent some of the fastest-developing types of medicines, but many still utilize hypodermic injections, which decrease compliance, require training, and typically necessitate cold chain. Microneedles represent a minimally invasive alternative to traditional hypodermic injection that also capitalizes on the immune-rich properties of the skin.
In this keynote, the developments in the area of solid, coated, hollow, dissolvable, and hydrogel-forming microneedles as well as different formulation techniques used to preserve the stability of molecular structure during manufacture, dehydration and storage through sugars and polymers or lipid nanoparticles and polyplexes will be reviewed.
The talk discusses design and formulation of microneedles that preserve the molecular structure of the drug, including use of sugars and polymers as well as liposomal nanoparticle encapsulation. It evaluates applications via pre-clinical work on vaccine delivery (influenza, SARS-CoV-2, mRNA) and dermatological gene silencing as well as phase 1 clinical trials of microneedle vaccine patches.
Despite promising preclinical results, there are still significant challenges in transitioning microneedle drug delivery technology to the clinic. The critical issues, such as scalability, sterility, stability and variability in dosing will be discussed. Priorities for the field will be defined with emphasis on the importance of the alignment of formulation, manufacturing and regulatory strategies.
Speaker
About the speaker
